The most developed TLR4-stimulating adjuvant is monophosphoryl lipid (MPL), the first to obtain approval for use in human vaccines against viral pathogens such as herpes zoster, Hepatitis B, and human papillomavirus (HPV) [35]. The gene discussed is TLR4; the disease is herpes zoster.